BioMarin Pharmaceutical Inc. (BMRN) compared with its closest peers (AMRX, ALNY, RPRX, SRPT, PTCT): P/E 176.9 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Amneal Pharmaceuticals, Alnylam Pharmaceuticals, Royalty Pharma, Sarepta Therapeutics, PTC Therapeutics, Organon, Phibro Animal Health, Indivior Pharmaceuticals, Lakefront Biotherapeutics and Prestige Consumer Healthcare share BioMarin Pharmaceutical's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $5.71B | 36.3 |
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.53B | 108.0 |
| Royalty Pharma plc (RPRX) | $34.13B | 41.3 |
| Sarepta Therapeutics, Inc. (SRPT) | $1.98B | -3.0 |
| PTC Therapeutics, Inc. (PTCT) | $5.83B | 9.8 |
| Organon & Co. (OGN) | $3.61B | 17.3 |
| Phibro Animal Health Corporation (PAHC) | $1.49B | 15.6 |
| Indivior Pharmaceuticals Inc (INDV) | $4.35B | 12.7 |
| Lakefront Biotherapeutics NV (LKFT) | $1.93B | 6.0 |
| Prestige Consumer Healthcare Inc. (PBH) | $2.43B | 14.1 |
| Stock P/E | 176.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 713.8% |
| vs Industry | 929.9% |
BMRN overview · BMRN earnings · BMRN financials · BMRN KPIs · BMRN documents · BMRN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.